Experimental One-Dose Treatment Cuts 'Bad' Cholesterol by 52% in First Human Trial
13 Articles
13 Articles
A study conducted by doctors and researchers at the Cleveland Clinic American Medical Foundation, in collaboration with researchers from Australia and New Zealand, showed that one dose of experimental genetic therapy contributed to lower levels of harmful cholesterol and triple fat in people with blood fat disorders.
CRISPR gene-editing therapy safely and continuously lowers cholesterol and triglycerides, first-in-human trial shows
A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL ("bad") cholesterol and triglycerides in people with medication-resistant lipid disorders through one year of follow-up across all doses.
SCIENTISTS are developing a CRISPR gene therapy that could permanently lower bad cholesterol with a single dose. The first human trial shows significant reductions in LDL and triglycerides a year after administration.
Experimental One-Dose Treatment Cuts 'Bad' Cholesterol by 52% in First Human Trial
Too much 'bad' cholesterol in the bloodstream – that's the low-density lipoprotein (LDL) type – can contribute to plaque buildup in the arteries, increasing the risk of cardiovascular problems like heart attacks and strokes.
Single-Dose CRISPR Therapy Significantly Lowers LDL Cholesterol for Year
A single-dose CRISPR therapy has been shown to significantly lower LDL cholesterol levels for a full year, according to new research. This breakthrough suggests promising potential for long-term management of cholesterol and related cardiovascular risks.
A clinical trial in 15 patients suggests that a single genetic treatment can permanently reduce LDL, but we are still in the early stages of testing.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
